Acute Kidney Injury Treated With a Mood Stabilizing Drug

by Dr. Enozia Vakil on  January 10, 2014 at 3:14 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

A new study found how acute kidney injury may now be treated with a mood stabilizing drug. The findings are significant because there are no effective therapies for AKI.
 Acute Kidney Injury Treated With a Mood Stabilizing Drug
Acute Kidney Injury Treated With a Mood Stabilizing Drug

AKI, an abrupt decline in kidney function, is an increasingly prevalent and potentially serious condition that can arise following trauma, sepsis, major surgery, or exposure to drugs that are toxic to the kidneys. Once the injury develops, patients have few established treatment options besides supportive care. AKI afflicts about 5% of all hospitalized patients and approximately 25% to 30% of patients in intensive care units. AKI is one of the most expensive conditions seen in US hospitals, costing the facilities several billions of dollars each year.

Research has shown that glycogen synthase kinase (GSK) 3β is an enzyme that plays a major role in the development of AKI. Fortunately, GSK3β can be blocked by using inhibitors, including novel small molecule chemical compounds and lithium.

Lithium is an FDA-approved mood stabilizer safely used for the past 50 years to treat bipolar affective disorders, but it carries significant side effects when used long-term. Hui Bao, MD, PhD, Rujun Gong, MD, PhD (Rhode Island Hospital, Brown University School of Medicine), and their colleagues discovered that giving mice a single low dose of lithium following AKI blocks GSK3β in injured kidneys, promotes kidney repair, and accelerates the recovery of kidney function.

"Our work suggests that lithium might represent a novel, pragmatic, and affordable therapy to improve kidney recovery after AKI," said Dr. Gong.

More pre-clinical studies are warranted to see if targeting GSK3β with lithium can improve long-term kidney health. Also, clinical trials are needed to determine the appropriate dose of lithium to promote kidney recovery following AKI in humans.

In an accompanying editorial, Man Livingston, PhD and Zheng Dong, PhD (Medical College of Georgia at Georgia Regents University and Charlie Norwood Veterans Affairs Medical Center) noted that "this study, by demonstrating the effect of lithium on tubular regeneration and repair in AKI, has significantly extended our knowledge of this drug and may broaden its potential therapeutic applications in kidney diseases."

Study co-authors include Yan Ge, MS, Zhen Wang, MD, PhD, Shougang Zhuang, MD, PhD, Lance Dworkin, MD, and Ai Peng, MD.

Disclosures: This study was made possible in part by the funding from the US National Institutes of Health grant R01DK092485 and the International Society of Nephrology (ISN) Sister Renal Center Trio Program. Dr. Hui Bao was an ISN fellow and a visiting nephrologist at Brown Medical School from Tongji University in Shanghai, China under the support of the ISN fellowship.

Source: Newswise

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Athletes Foot Urinary Stones In Children Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Urology Paediatric Emergencies Cysts and Tumours Signature Drug Toxicity Kidney Disease Kidney 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive